ArticleBJU international2026
Intravesical oxybutynin for bladder capacity in children with spina bifida: the 'Place de l'OXybutynine Intravésicale chez le Patient Enfant Neurologique' (POXIPEN) trial protocol.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07027020 (Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial
Who cites it
1 citing paper in PubMed.
- Advancements in the Treatment and Management of Voiding Dysfunction in Individuals with Spina Bifida.Current urology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNeurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery. Given the risk of repeated general anaesthesia in children, there is a need for non-invasive treatment for young patients who do not respond to or have adverse effects from oral anticholinergic treatment. The 'Place de l'OXybutynine Intravésicale chez le Patient Enfant Neurologique' (POXIPEN) trial aims to assess the efficacy of intra-vesical oxybutynin on bladder capacity in a sample of French children with neurogenic bladder. STUDY
designThe POXIPEN is a multicentre, randomised, double-blind, placebo-controlled trial. ENDPOINTS: The primary outcome is change in maximal bladder capacity after treatment. Secondary outcomes include changes in voiding, urodynamic and ultrasound parameters. We will also assess changes on quality of life and usability of the product. PATIENTS AND
methodsWe aim to randomly assign 60 children with neurogenic bladder secondary to spina bifida and deemed non-responders to first-line treatment with oral anticholinergics, to receive intravesical oxybutynin (IVO) or placebo for 4 weeks. Recruitment will start in September 2025. It will be the first prospective study to evaluate the efficacy of IVO in children, with a high level of evidence provided by its design. If IVO proves effective, it could lengthen the delay in therapeutic escalation to invasive procedures, thereby reducing the risk of complications associated with general anaesthesia in children with neurogenic bladder.
trial registrationThis trial is registered with the European Union (EU) Clinical Trials Information System (CTIS) under EU CT Number: 2022-501 902-36-00 (approved 09.01.2025) and ClinicalTrials.gov under identifier NCT07027020 (registered 18.06.2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.